| Nov 15 |
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
|
| Nov 13 |
Longeveron reports Q3 results
|
| Nov 13 |
LGVN Highlights Potential Groundbreaking Treatments
|
| Nov 13 |
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
|
| Nov 4 |
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
|
| Oct 29 |
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
|
| Oct 28 |
LGVN Announces Treatment Garners Excellent Results
|
